首页 > 最新文献

JCO precision oncology最新文献

英文 中文
Assessing the Value of Sequential Next-Generation Sequencing and Multiple Molecular Tumor Board Reviews for Patients With Solid-Tumor Malignancies. 评估下一代序列测序和多分子肿瘤委员会对实体肿瘤恶性肿瘤患者的价值。
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-15 DOI: 10.1200/PO-25-00272
Allison L Swiecki-Sikora, Lydia Williams, Ning Li, Donglin Yan, Evan Bryson, Derek B Allison, Rachel W Miller, Charles S Dietrich, Jill M Kolesar

Purpose: Multidisciplinary molecular tumor boards (MTBs) have demonstrated improved clinical outcomes in various malignancies. Sequential next-generation sequencing (NGS) is widely performed at the time of recurrence, which may lead to multiple MTB reviews. This study assessed the clinical benefit of multiple MTB reviews for sequential NGS.

Methods: A retrospective cohort review was performed to compare patients reviewed once at a single-institution MTB and those reviewed multiple times for the same diagnosis with sequential NGS between January 2016 and December 2023. Demographics were compared, and regression and survival analysis was performed.

Results: In all, 3,702 patients were included, 3,446 (91.6%) were reviewed once, and 256 (8.4%) were reviewed multiple times. Patients reviewed once had higher proportion of actionable findings (52.7% v 44.5%, P = .01) compared with those reviewed multiple times at initial review. Approximately half of the patients at their second (47.3%) and third or more (62.5%) reviews had actionable findings. The mean time on recommended targeted therapy for patients reviewed multiple times was 8.24 months (standard deviation [SD], 9.34; range, 0.07-42.4), and the mean time on recommended immunotherapy was 7.02 months (SD, 9.47; range, 0.1-39.2). Patients with multiple MTB reviews had a 30% lower risk of death compared with those reviewed once, even after controlling for primary site, age, presence of actionable NGS findings, and stage (hazard ratio, 0.7, 95% CI, 0.55 to 0.89; P = .004).

Conclusion: Sequential NGS identified actionable findings in approximately 50% of those with multiple reviews, and many patients stay on recommended therapy for at least 6 months. Patients with sequential NGS and multiple reviews have a survival advantage, and although this may be due to therapy sensitivity, it reflects the importance of NGS testing and usefulness of MTB in interpreting those results.

目的:多学科分子肿瘤委员会(MTBs)已经证明改善了各种恶性肿瘤的临床结果。序贯下一代测序(NGS)广泛用于复发时,这可能导致多次MTB审查。本研究评估了对序贯NGS进行多次MTB回顾的临床获益。方法:在2016年1月至2023年12月期间,进行回顾性队列研究,比较在单一机构MTB接受一次审查的患者和在同一诊断下接受顺序NGS多次审查的患者。进行人口统计学比较,并进行回归分析和生存分析。结果:共纳入3702例患者,一次回顾3446例(91.6%),多次回顾256例(8.4%)。与首次复查时多次复查的患者相比,一次复查的患者可操作发现的比例更高(52.7% vs 44.5%, P = 0.01)。大约一半的患者在他们的第二次(47.3%)和第三次或更多(62.5%)审查中有可操作的发现。多次复查患者推荐靶向治疗的平均时间为8.24个月(标准差[SD], 9.34,范围0.07-42.4),推荐免疫治疗的平均时间为7.02个月(SD, 9.47,范围0.1-39.2)。即使在控制了原发部位、年龄、可操作的NGS检查结果和分期后,接受多次MTB复查的患者的死亡风险也比接受一次复查的患者低30%(风险比为0.7,95% CI为0.55 ~ 0.89;P = 0.004)。结论:序贯NGS在约50%的多次评价中发现了可操作的结果,许多患者坚持推荐的治疗至少6个月。序贯NGS和多次评价的患者具有生存优势,尽管这可能是由于治疗敏感性,但它反映了NGS检测的重要性和MTB在解释这些结果时的有用性。
{"title":"Assessing the Value of Sequential Next-Generation Sequencing and Multiple Molecular Tumor Board Reviews for Patients With Solid-Tumor Malignancies.","authors":"Allison L Swiecki-Sikora, Lydia Williams, Ning Li, Donglin Yan, Evan Bryson, Derek B Allison, Rachel W Miller, Charles S Dietrich, Jill M Kolesar","doi":"10.1200/PO-25-00272","DOIUrl":"10.1200/PO-25-00272","url":null,"abstract":"<p><strong>Purpose: </strong>Multidisciplinary molecular tumor boards (MTBs) have demonstrated improved clinical outcomes in various malignancies. Sequential next-generation sequencing (NGS) is widely performed at the time of recurrence, which may lead to multiple MTB reviews. This study assessed the clinical benefit of multiple MTB reviews for sequential NGS.</p><p><strong>Methods: </strong>A retrospective cohort review was performed to compare patients reviewed once at a single-institution MTB and those reviewed multiple times for the same diagnosis with sequential NGS between January 2016 and December 2023. Demographics were compared, and regression and survival analysis was performed.</p><p><strong>Results: </strong>In all, 3,702 patients were included, 3,446 (91.6%) were reviewed once, and 256 (8.4%) were reviewed multiple times. Patients reviewed once had higher proportion of actionable findings (52.7% <i>v</i> 44.5%, <i>P</i> = .01) compared with those reviewed multiple times at initial review. Approximately half of the patients at their second (47.3%) and third or more (62.5%) reviews had actionable findings. The mean time on recommended targeted therapy for patients reviewed multiple times was 8.24 months (standard deviation [SD], 9.34; range, 0.07-42.4), and the mean time on recommended immunotherapy was 7.02 months (SD, 9.47; range, 0.1-39.2). Patients with multiple MTB reviews had a 30% lower risk of death compared with those reviewed once, even after controlling for primary site, age, presence of actionable NGS findings, and stage (hazard ratio, 0.7, 95% CI, 0.55 to 0.89; <i>P</i> = .004).</p><p><strong>Conclusion: </strong>Sequential NGS identified actionable findings in approximately 50% of those with multiple reviews, and many patients stay on recommended therapy for at least 6 months. Patients with sequential NGS and multiple reviews have a survival advantage, and although this may be due to therapy sensitivity, it reflects the importance of NGS testing and usefulness of MTB in interpreting those results.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 ","pages":"e2500272"},"PeriodicalIF":5.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12810861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network. 促进分子肿瘤学时代临床试验实施的创新研究组织:肿瘤区分网络的蜘蛛网模型。
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-21 DOI: 10.1200/PO-25-00953
Simon Nannini, Anthony Goncalves, Carlos Gomez-Roca, Demetris Papamichael, Ikram El Idrissi, Ahmad Awada, Nuria Kotecki
{"title":"Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network.","authors":"Simon Nannini, Anthony Goncalves, Carlos Gomez-Roca, Demetris Papamichael, Ikram El Idrissi, Ahmad Awada, Nuria Kotecki","doi":"10.1200/PO-25-00953","DOIUrl":"https://doi.org/10.1200/PO-25-00953","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 ","pages":"e2500953"},"PeriodicalIF":5.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Hereditary Cancer Susceptibility in Solid-Organ Transplant Recipients. 实体器官移植受者遗传癌症易感性的影响。
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-23 DOI: 10.1200/PO-25-00787
Nicholas Khuu, Marie Jeanjean, Talia Donenberg, Rachel Silva Smith, Daniel Sussman, Rodrigo Vianna, Gaetano Ciancio, Yan Guo, Mustafa Tekin, Nicholas A Borja
{"title":"Impact of Hereditary Cancer Susceptibility in Solid-Organ Transplant Recipients.","authors":"Nicholas Khuu, Marie Jeanjean, Talia Donenberg, Rachel Silva Smith, Daniel Sussman, Rodrigo Vianna, Gaetano Ciancio, Yan Guo, Mustafa Tekin, Nicholas A Borja","doi":"10.1200/PO-25-00787","DOIUrl":"10.1200/PO-25-00787","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 ","pages":"e2500787"},"PeriodicalIF":5.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation. 肿瘤信息循环肿瘤DNA检测分子残留疾病分析验证通用方案:癌症分子残留疾病分析验证工作组共识推荐的血液图谱。
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-14 DOI: 10.1200/PO-25-00267
Jonathan Baden, Cheng-Ho Jimmy Lin, Andrew T Anfora, Jonathan Beer, Karl Bisselou, Jennifer Bungo, Adam S Corner, Tyler Danek, Jennifer Dickey, James H Godsey, Donald J Johann, Gregory Jones, George Karlin-Neumann, Jessica L Larson, Jerry S H Lee, Li Liu, Dorys Lopez Ramos, David Merriam, Melanie Palomares, Carol E Pena, Jessica Rathbun, Kate Rhodes, Jaime E Connolly Rohrbach, Banu Saritas-Yildirim, Mark Sausen, Shile Zhang, Lauren C Leiman

The presence of circulating tumor DNA (ctDNA) in patients indicates post-treatment molecular residual disease (MRD). Given the complexity of ctDNA-based MRD detection tests, consensus on analytical validation (AV) criteria is needed. To address this, the Blood Profiling Atlas in Cancer (BLOODPAC) Consortium's MRD AV Working Group evaluated existing protocols to develop standardized guidance for tumor-informed assays. Protocols pertaining to blood collection tube types, quantitative output, tissue processing, tumor or matched normal sequencing, software, and clinical validation were considered out of scope. After alignment on objectives and assumptions, study designs on the basis of best practices in the field, available assay validation guidance documents, and unique performance challenges for tumor-informed MRD assays were authored. Each protocol contains introduction, experimental design, statistical analysis, and an example data presentation per the US Food and Drug Administration (FDA) Center for Devices and Radiological Health standard format. Biostatisticians were consulted to define minimal test requirements, sample size, and appropriate statistical analyses. The protocols were submitted to the FDA via the presubmission process for formal written feedback followed by a meeting. BLOODPAC's generic protocols for the AV of tumor-informed ctDNA assays for MRD are designed to provide test developers with a core baseline of standardized AV protocols such that methods described can be adapted and applied for any tumor-informed MRD assay irrespective of technology, panel design algorithm, or workflow component. These protocols aim to optimize test developers' presubmission reviews with the FDA, ensuring productive meetings while enabling reviewers to streamline feedback. As always, test developers are encouraged to communicate with FDA directly around their particular AV methods.

患者体内循环肿瘤DNA (ctDNA)的存在提示治疗后分子残留疾病(MRD)。鉴于基于ctdna的MRD检测测试的复杂性,需要对分析验证(AV)标准达成共识。为了解决这个问题,癌症血液图谱(BLOODPAC)联盟的MRD AV工作组评估了现有的协议,以制定肿瘤检测的标准化指导。有关采血管类型、定量输出、组织处理、肿瘤或匹配正常测序、软件和临床验证的方案被认为不在讨论范围之内。在对目标和假设进行调整后,基于该领域最佳实践的研究设计、可用的分析验证指导文件以及针对肿瘤的MRD分析的独特性能挑战被撰写。每个方案包含介绍,实验设计,统计分析,并根据美国食品和药物管理局(FDA)设备和放射卫生中心标准格式的示例数据演示。咨询了生物统计学家来确定最小测试要求、样本量和适当的统计分析。这些方案通过预提交程序提交给FDA,以获得正式的书面反馈,然后举行会议。BLOODPAC的MRD ctDNA检测的AV通用协议旨在为测试开发人员提供标准化AV协议的核心基线,这样所描述的方法可以适用于任何肿瘤的MRD检测,而不考虑技术、面板设计算法或工作流程组件。这些协议旨在优化测试开发人员与FDA的预提交审查,确保富有成效的会议,同时使审稿人能够简化反馈。与往常一样,鼓励测试开发人员直接与FDA就其特定的AV方法进行沟通。
{"title":"Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation.","authors":"Jonathan Baden, Cheng-Ho Jimmy Lin, Andrew T Anfora, Jonathan Beer, Karl Bisselou, Jennifer Bungo, Adam S Corner, Tyler Danek, Jennifer Dickey, James H Godsey, Donald J Johann, Gregory Jones, George Karlin-Neumann, Jessica L Larson, Jerry S H Lee, Li Liu, Dorys Lopez Ramos, David Merriam, Melanie Palomares, Carol E Pena, Jessica Rathbun, Kate Rhodes, Jaime E Connolly Rohrbach, Banu Saritas-Yildirim, Mark Sausen, Shile Zhang, Lauren C Leiman","doi":"10.1200/PO-25-00267","DOIUrl":"10.1200/PO-25-00267","url":null,"abstract":"<p><p>The presence of circulating tumor DNA (ctDNA) in patients indicates post-treatment molecular residual disease (MRD). Given the complexity of ctDNA-based MRD detection tests, consensus on analytical validation (AV) criteria is needed. To address this, the Blood Profiling Atlas in Cancer (BLOODPAC) Consortium's MRD AV Working Group evaluated existing protocols to develop standardized guidance for tumor-informed assays. Protocols pertaining to blood collection tube types, quantitative output, tissue processing, tumor or matched normal sequencing, software, and clinical validation were considered out of scope. After alignment on objectives and assumptions, study designs on the basis of best practices in the field, available assay validation guidance documents, and unique performance challenges for tumor-informed MRD assays were authored. Each protocol contains introduction, experimental design, statistical analysis, and an example data presentation per the US Food and Drug Administration (FDA) Center for Devices and Radiological Health standard format. Biostatisticians were consulted to define minimal test requirements, sample size, and appropriate statistical analyses. The protocols were submitted to the FDA via the presubmission process for formal written feedback followed by a meeting. BLOODPAC's generic protocols for the AV of tumor-informed ctDNA assays for MRD are designed to provide test developers with a core baseline of standardized AV protocols such that methods described can be adapted and applied for any tumor-informed MRD assay irrespective of technology, panel design algorithm, or workflow component. These protocols aim to optimize test developers' presubmission reviews with the FDA, ensuring productive meetings while enabling reviewers to streamline feedback. As always, test developers are encouraged to communicate with FDA directly around their particular AV methods.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 ","pages":"e2500267"},"PeriodicalIF":5.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer: A Study Based on a Japanese Cancer Genome Database. 基于日本癌症基因组数据库的ras扩增结直肠癌基因组谱和抗表皮生长因子受体抗体耐药性研究
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-08 DOI: 10.1200/PO-25-00424
Gota Fujisawa, Kenji Tamada, Takeshi Hayashi, Nobumi Suzuki, Takuma Iwata, Yu Miyakawa, Masahiro Hata, Rei Ishibashi, Yoku Hayakawa, Aya Shinozaki-Ushiku, Hidenori Kage, Katsutoshi Oda, Narikazu Boku, Mitsuhiro Fujishiro

Purpose: RAS mutation is a key biomarker of anti-epidermal growth factor receptor (EGFR) antibody resistance in colorectal cancer (CRC). However, the clinical impact of RAS amplification on the efficacy of anti-EGFR therapy remains unclear. This study aimed to characterize RAS-amplified CRC and evaluate the sensitivity of these tumors to anti-EGFR antibodies.

Methods: We conducted a retrospective observational study using the Center for Cancer Genomics and Advanced Therapeutics database in Japan, which includes clinical and genomic data from patients who underwent comprehensive genomic profiling. We analyzed the data from 9,135 patients with unresectable colorectal adenocarcinoma (CRA) who underwent FoundationOne CDx testing.

Results: RAS amplification was identified in 2.1% (188/9,135) of patients with CRA. Among 1,649 patients with RAS wild-type CRA who received first-line chemotherapy with anti-EGFR antibodies, those with RAS amplification had a lower overall response rate (ORR) and a shorter time to treatment failure (TTF) compared with those without RAS amplification (ORR, 37.5% [21/56] v 52.9% [843/1,593]; median TTF, 195 days [95% CI, 129 to 224] v 274 days [95% CI, 258 to 293]; P = .023 and P = .005, respectively). By contrast, among 4,858 patients treated with bevacizumab, no significant differences were observed in ORR (37.3% [31/83] v 37.1% [1,772/4,775]; P = .964) or TTF (median, 231 days [95% CI, 175 to 273] v 259 days [95% CI, 252 to 270]; P = .445).

Conclusion: RAS amplification is a rare alteration that may confer resistance to anti-EGFR antibodies. Assessing RAS amplification status may help guide the appropriate use of anti-EGFR antibodies in clinical practice.

目的:RAS突变是结直肠癌(CRC)抗表皮生长因子受体(EGFR)抗体耐药的关键生物标志物。然而,RAS扩增对抗egfr治疗效果的临床影响尚不清楚。本研究旨在表征ras扩增的结直肠癌,并评估这些肿瘤对抗egfr抗体的敏感性。方法:我们使用日本癌症基因组学和高级治疗中心的数据库进行了一项回顾性观察研究,其中包括来自接受全面基因组分析的患者的临床和基因组数据。我们分析了9,135例接受FoundationOne CDx检测的不可切除结直肠癌(CRA)患者的数据。结果:2.1%(188/ 9135)的CRA患者检测到RAS扩增。在1,649例接受抗egfr抗体一线化疗的RAS野生型CRA患者中,RAS扩增患者的总有效率(ORR)较低,治疗失败时间(TTF)较无RAS扩增患者短(ORR为37.5% [21/56]vs 52.9%[843/ 1593];中位TTF为195天[95% CI, 129 ~ 224] vs 274天[95% CI, 258 ~ 293]; P = 0.023和P = 0.005)。相比之下,在4858例接受贝伐单抗治疗的患者中,ORR (37.3% [31/83] vs 37.1% [1772 / 4775]; P = 0.964)或TTF(中位,231天[95% CI, 175 ~ 273] vs 259天[95% CI, 252 ~ 270]; P = 0.445)无显著差异。结论:RAS扩增是一种罕见的变异,可能导致对抗egfr抗体产生耐药性。评估RAS扩增状态可能有助于指导临床实践中抗egfr抗体的适当使用。
{"title":"Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer: A Study Based on a Japanese Cancer Genome Database.","authors":"Gota Fujisawa, Kenji Tamada, Takeshi Hayashi, Nobumi Suzuki, Takuma Iwata, Yu Miyakawa, Masahiro Hata, Rei Ishibashi, Yoku Hayakawa, Aya Shinozaki-Ushiku, Hidenori Kage, Katsutoshi Oda, Narikazu Boku, Mitsuhiro Fujishiro","doi":"10.1200/PO-25-00424","DOIUrl":"10.1200/PO-25-00424","url":null,"abstract":"<p><strong>Purpose: </strong>RAS mutation is a key biomarker of anti-epidermal growth factor receptor (EGFR) antibody resistance in colorectal cancer (CRC). However, the clinical impact of RAS amplification on the efficacy of anti-EGFR therapy remains unclear. This study aimed to characterize RAS-amplified CRC and evaluate the sensitivity of these tumors to anti-EGFR antibodies.</p><p><strong>Methods: </strong>We conducted a retrospective observational study using the Center for Cancer Genomics and Advanced Therapeutics database in Japan, which includes clinical and genomic data from patients who underwent comprehensive genomic profiling. We analyzed the data from 9,135 patients with unresectable colorectal adenocarcinoma (CRA) who underwent FoundationOne CDx testing.</p><p><strong>Results: </strong>RAS amplification was identified in 2.1% (188/9,135) of patients with CRA. Among 1,649 patients with RAS wild-type CRA who received first-line chemotherapy with anti-EGFR antibodies, those with RAS amplification had a lower overall response rate (ORR) and a shorter time to treatment failure (TTF) compared with those without RAS amplification (ORR, 37.5% [21/56] <i>v</i> 52.9% [843/1,593]; median TTF, 195 days [95% CI, 129 to 224] <i>v</i> 274 days [95% CI, 258 to 293]; <i>P</i> = .023 and <i>P</i> = .005, respectively). By contrast, among 4,858 patients treated with bevacizumab, no significant differences were observed in ORR (37.3% [31/83] <i>v</i> 37.1% [1,772/4,775]; <i>P</i> = .964) or TTF (median, 231 days [95% CI, 175 to 273] <i>v</i> 259 days [95% CI, 252 to 270]; <i>P</i> = .445).</p><p><strong>Conclusion: </strong>RAS amplification is a rare alteration that may confer resistance to anti-EGFR antibodies. Assessing RAS amplification status may help guide the appropriate use of anti-EGFR antibodies in clinical practice.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 ","pages":"e2500424"},"PeriodicalIF":5.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Characterization of a Complex PDGFRB Structural Variation in Infantile Myofibroma With Complete Response to Imatinib. 对伊马替尼完全有效的婴儿肌纤维瘤中复杂PDGFRB结构变异的分子特征
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-14 DOI: 10.1200/PO-25-00943
Wynn E Bastianelli, Jinhua Wu, Mian Umair Ahsan, Ava M Szepessy, Jeffery Schubert, Naomi J Balamuth, Joe Chan, Elizabeth H Denenberg, Minjie Luo, Avrum N Pollock, Pierre A Russo, Karleena Rybacki, Feng Xu, Yiming Zhong, Lea F Surrey, Kai Wang, Theodore W Laetsch, Marilyn M Li
{"title":"Molecular Characterization of a Complex <i>PDGFRB</i> Structural Variation in Infantile Myofibroma With Complete Response to Imatinib.","authors":"Wynn E Bastianelli, Jinhua Wu, Mian Umair Ahsan, Ava M Szepessy, Jeffery Schubert, Naomi J Balamuth, Joe Chan, Elizabeth H Denenberg, Minjie Luo, Avrum N Pollock, Pierre A Russo, Karleena Rybacki, Feng Xu, Yiming Zhong, Lea F Surrey, Kai Wang, Theodore W Laetsch, Marilyn M Li","doi":"10.1200/PO-25-00943","DOIUrl":"10.1200/PO-25-00943","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 ","pages":"e2500943"},"PeriodicalIF":5.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olaparib Response in a Patient With Platinum-Refractory Germ Cell Tumor Harboring a Somatic BRIP1 Mutation. 携带体细胞BRIP1突变的铂难治性生殖细胞肿瘤患者的奥拉帕尼应答
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-08 DOI: 10.1200/PO-25-00768
Camila Bobato Lara Gismondi, Ruchi Agarwal, Maria Fernanda Botelho Teixeira, Alexander Chehrazi-Raffle
{"title":"Olaparib Response in a Patient With Platinum-Refractory Germ Cell Tumor Harboring a Somatic <i>BRIP1</i> Mutation.","authors":"Camila Bobato Lara Gismondi, Ruchi Agarwal, Maria Fernanda Botelho Teixeira, Alexander Chehrazi-Raffle","doi":"10.1200/PO-25-00768","DOIUrl":"10.1200/PO-25-00768","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 ","pages":"e2500768"},"PeriodicalIF":5.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis. ATR抑制剂在儿童恶性肿瘤中的发展途径:加速多利益相关者分析。
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-15 DOI: 10.1200/PO-25-00642
Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, Michael V Ortiz, Ronald Bernardi, Lou Chesler, Steve Clifford, Sarah Cohen-Gogo, Esther De La Cuesta, Teresa de Rojas, Kaat Durinck, Sara Federico, Elizabeth Fox, Sally George, Ioannis Gounaris, Anton George Henssen, Meredith Irwin, Marcel Kool, Alan Lau, Karsten Nysom, Alberto Pappo, Gregory K Pennock, Stefan M Pfister, Nicole Scobie, Emily K Slotkin, Malcolm Smith, Frank Speleman, Elizabeth A Stewart, Brenda J Weigel, Gilles Vassal

Purpose: High levels of DNA replication stress and defects in the DNA damage response (DDR) pathways are vulnerabilities of many poor prognosis childhood malignancies. Ataxia telangiectasia and Rad3-related protein (ATR) is a key regulator of these pathways and constitutes an attractive target, especially in combination. However, the malignancies where ATR inhibitors have maximum benefit and synergistic combinations differ between adults and children.

Design: ACCELERATE convened a multistakeholder meeting and conducted review and analysis to propose the optimal pathway for the development of ATR inhibitors in pediatric malignancies.

Results: Considering the lack of identified biomarkers, the initial evaluation of ATR inhibitors should focus on Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma in view of their high levels of DNA replication stress and defects in DDR pathways. Early phase trials of ATR inhibitors should be iterative, based on a clear hypothesis with responders and nonresponders undergoing detailed molecular analysis and a revised new hypothesis generated. Trial designs should restrict monotherapy evaluation to a brief exposure in a small number of patients and progress rapidly to combinations. Highlighted combination partners are poly(ADP-ribose) polymerase inhibitors and antibody drug conjugates with topoisomerase I inhibitor payloads. Combinations with ALK inhibitors (in ALK/MYCN-aberrant neuroblastoma) and aurora A kinase (in MYCN-amplified) are supported by robust mechanisms of action and preclinical data. Early interactions with regulators are crucial, and early phase clinical trials should be conducted in regulatory-approved, academic-sponsored, industry-supported, platform trials.

Conclusion: ATR inhibitors are a prototype for the development of medicinal products in a limited pediatric population. For the substantial potential of ATR inhibitors in children with malignancy to be realized, strategic planning between academia, industry, regulators, and patient advocates is vital.

目的:高水平的DNA复制应激和DNA损伤反应(DDR)通路的缺陷是许多预后不良的儿童恶性肿瘤的脆弱性。共济失调毛细血管扩张和rad3相关蛋白(ATR)是这些途径的关键调节因子,构成了一个有吸引力的靶标,特别是在联合使用时。然而,ATR抑制剂对恶性肿瘤的最大益处和协同作用组合在成人和儿童之间有所不同。设计:ACCELERATE召集了多方利益相关者会议,并进行了回顾和分析,以提出开发ATR抑制剂治疗儿科恶性肿瘤的最佳途径。结果:考虑到缺乏确定的生物标志物,鉴于Ewing肉瘤、横纹肌肉瘤和神经母细胞瘤的DNA复制应激水平高,DDR通路存在缺陷,ATR抑制剂的初步评估应侧重于这些肿瘤。ATR抑制剂的早期试验应该是迭代的,基于一个明确的假设,对反应者和无反应者进行详细的分子分析,并产生一个修订的新假设。试验设计应限制单药治疗评估在少数患者中的短暂暴露,并迅速进展到联合治疗。重点强调的组合伙伴是poly(adp -核糖)聚合酶抑制剂和抗体药物偶联物与拓扑异构酶I抑制剂有效载荷。与ALK抑制剂(在ALK/ mycn异常的神经母细胞瘤中)和aurora A激酶(在mycn扩增的神经母细胞瘤中)联合使用得到了强大的作用机制和临床前数据的支持。与监管机构的早期互动至关重要,早期临床试验应在监管机构批准、学术赞助、行业支持的平台试验中进行。结论:ATR抑制剂是在有限的儿科人群中开发医药产品的原型。为了实现ATR抑制剂在恶性肿瘤儿童中的巨大潜力,学术界、工业界、监管机构和患者倡导者之间的战略规划至关重要。
{"title":"Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis.","authors":"Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, Michael V Ortiz, Ronald Bernardi, Lou Chesler, Steve Clifford, Sarah Cohen-Gogo, Esther De La Cuesta, Teresa de Rojas, Kaat Durinck, Sara Federico, Elizabeth Fox, Sally George, Ioannis Gounaris, Anton George Henssen, Meredith Irwin, Marcel Kool, Alan Lau, Karsten Nysom, Alberto Pappo, Gregory K Pennock, Stefan M Pfister, Nicole Scobie, Emily K Slotkin, Malcolm Smith, Frank Speleman, Elizabeth A Stewart, Brenda J Weigel, Gilles Vassal","doi":"10.1200/PO-25-00642","DOIUrl":"10.1200/PO-25-00642","url":null,"abstract":"<p><strong>Purpose: </strong>High levels of DNA replication stress and defects in the DNA damage response (DDR) pathways are vulnerabilities of many poor prognosis childhood malignancies. Ataxia telangiectasia and Rad3-related protein (ATR) is a key regulator of these pathways and constitutes an attractive target, especially in combination. However, the malignancies where ATR inhibitors have maximum benefit and synergistic combinations differ between adults and children.</p><p><strong>Design: </strong>ACCELERATE convened a multistakeholder meeting and conducted review and analysis to propose the optimal pathway for the development of ATR inhibitors in pediatric malignancies.</p><p><strong>Results: </strong>Considering the lack of identified biomarkers, the initial evaluation of ATR inhibitors should focus on Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma in view of their high levels of DNA replication stress and defects in DDR pathways. Early phase trials of ATR inhibitors should be iterative, based on a clear hypothesis with responders and nonresponders undergoing detailed molecular analysis and a revised new hypothesis generated. Trial designs should restrict monotherapy evaluation to a brief exposure in a small number of patients and progress rapidly to combinations. Highlighted combination partners are poly(ADP-ribose) polymerase inhibitors and antibody drug conjugates with topoisomerase I inhibitor payloads. Combinations with ALK inhibitors (in <i>ALK</i>/<i>MYCN</i>-aberrant neuroblastoma) and aurora A kinase (in <i>MYCN</i>-amplified) are supported by robust mechanisms of action and preclinical data. Early interactions with regulators are crucial, and early phase clinical trials should be conducted in regulatory-approved, academic-sponsored, industry-supported, platform trials.</p><p><strong>Conclusion: </strong>ATR inhibitors are a prototype for the development of medicinal products in a limited pediatric population. For the substantial potential of ATR inhibitors in children with malignancy to be realized, strategic planning between academia, industry, regulators, and patient advocates is vital.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 ","pages":"e2500642"},"PeriodicalIF":5.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long Short-Term Memory-Driven Modeling of Dynamic Hepatocellular Carcinoma Microenvironments: A Deep Learning Framework for Precision Treatment Prediction. 动态肝细胞癌微环境的长短期记忆驱动建模:用于精确治疗预测的深度学习框架。
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2025-12-01 Epub Date: 2025-12-10 DOI: 10.1200/PO-25-00315
Hai Zhong, Bin Wu, Xiaodan Yang, Xiaoguang Wang, Minjie Chen, Lingyu Hu

Purpose: This study evaluates deep learning (DL) approaches, particularly long short-term memory (LSTM) networks, for analyzing dynamic changes in the hepatocellular carcinoma (HCC) tumor microenvironment (TME) to improve disease understanding and treatment prediction.

Materials and methods: Multimodal HCC TME data (high-throughput sequencing, protein expression, and time-series imaging) were integrated. Spatial features were extracted using convolutional neural networks (CNNs), while temporal patterns were modeled with LSTMs. Generative adversarial networks (GANs) augmented data for robust training. Model performance was assessed on the basis of dynamic TME characterization and outcome prediction accuracy.

Results: LSTMs demonstrated superior performance in analyzing TME time-series data, effectively capturing long-term dependencies and predicting cellular interactions (accuracy: 92.3% v 85.7% for CNNs alone). The integrated DL framework successfully characterized spatiotemporal TME evolution and treatment response patterns.

Conclusion: This study demonstrates that LSTMs are powerful tools for analyzing and understanding the dynamic changes in the HCC immune microenvironment. Their strong capability in time-series data analysis provides new opportunities for uncovering the mechanisms of HCC progression and optimizing therapeutic strategies. However, because of the lack of detailed etiological information, stratified validation across different etiologies such as hepatitis B virus, hepatitis C virus, and non-alcoholic steatohepatitis has not yet been conducted in this study and should be addressed in future work. The findings highlight the important role of DL technologies in future research and treatment of HCC.

目的:本研究评估了深度学习(DL)方法,特别是长短期记忆(LSTM)网络,用于分析肝细胞癌(HCC)肿瘤微环境(TME)的动态变化,以提高对疾病的认识和治疗预测。材料和方法:整合多模式HCC TME数据(高通量测序、蛋白表达和时间序列成像)。空间特征提取使用卷积神经网络(cnn),时间模式建模使用lstm。生成对抗网络(GANs)增强数据鲁棒性训练。根据动态TME表征和结果预测精度评估模型性能。结果:LSTMs在分析TME时间序列数据、有效捕获长期依赖关系和预测细胞相互作用方面表现出优异的性能(准确率:92.3% vs 85.7%单独使用cnn)。综合DL框架成功表征了TME的时空演化和治疗反应模式。结论:本研究表明lstm是分析和理解HCC免疫微环境动态变化的有力工具。他们强大的时间序列数据分析能力为揭示HCC进展机制和优化治疗策略提供了新的机会。然而,由于缺乏详细的病因学信息,本研究尚未对不同病因(如乙型肝炎病毒、丙型肝炎病毒和非酒精性脂肪性肝炎)进行分层验证,并应在未来的工作中加以解决。这些发现突出了DL技术在未来HCC研究和治疗中的重要作用。
{"title":"Long Short-Term Memory-Driven Modeling of Dynamic Hepatocellular Carcinoma Microenvironments: A Deep Learning Framework for Precision Treatment Prediction.","authors":"Hai Zhong, Bin Wu, Xiaodan Yang, Xiaoguang Wang, Minjie Chen, Lingyu Hu","doi":"10.1200/PO-25-00315","DOIUrl":"https://doi.org/10.1200/PO-25-00315","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluates deep learning (DL) approaches, particularly long short-term memory (LSTM) networks, for analyzing dynamic changes in the hepatocellular carcinoma (HCC) tumor microenvironment (TME) to improve disease understanding and treatment prediction.</p><p><strong>Materials and methods: </strong>Multimodal HCC TME data (high-throughput sequencing, protein expression, and time-series imaging) were integrated. Spatial features were extracted using convolutional neural networks (CNNs), while temporal patterns were modeled with LSTMs. Generative adversarial networks (GANs) augmented data for robust training. Model performance was assessed on the basis of dynamic TME characterization and outcome prediction accuracy.</p><p><strong>Results: </strong>LSTMs demonstrated superior performance in analyzing TME time-series data, effectively capturing long-term dependencies and predicting cellular interactions (accuracy: 92.3% <i>v</i> 85.7% for CNNs alone). The integrated DL framework successfully characterized spatiotemporal TME evolution and treatment response patterns.</p><p><strong>Conclusion: </strong>This study demonstrates that LSTMs are powerful tools for analyzing and understanding the dynamic changes in the HCC immune microenvironment. Their strong capability in time-series data analysis provides new opportunities for uncovering the mechanisms of HCC progression and optimizing therapeutic strategies. However, because of the lack of detailed etiological information, stratified validation across different etiologies such as hepatitis B virus, hepatitis C virus, and non-alcoholic steatohepatitis has not yet been conducted in this study and should be addressed in future work. The findings highlight the important role of DL technologies in future research and treatment of HCC.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"9 ","pages":"e2500315"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145723610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R-Mutated Metastatic Pancreatic Adenocarcinoma. 扩大对聚合酶Epsilon在胰腺癌中的理解:免疫检查点抑制剂在聚合酶Epsilon p286r突变的转移性胰腺腺癌中的应答
IF 5.6 2区 医学 Q1 ONCOLOGY Pub Date : 2025-12-01 Epub Date: 2025-12-10 DOI: 10.1200/PO-25-00521
Karthic Drishna Perumal, Kenneth Chian, Jinesh Gheeya, Asrar Alahmadi, Arjun Mittra, Mingjia Li
{"title":"Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R-Mutated Metastatic Pancreatic Adenocarcinoma.","authors":"Karthic Drishna Perumal, Kenneth Chian, Jinesh Gheeya, Asrar Alahmadi, Arjun Mittra, Mingjia Li","doi":"10.1200/PO-25-00521","DOIUrl":"https://doi.org/10.1200/PO-25-00521","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"9 ","pages":"e2500521"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145723618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JCO precision oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1